Lung Cancer
Conference Coverage
PD-L1 testing in NSCLC patients shows high concordance
VIENNA - Several different tests for PD-L1 levels in tumor cells of patients with metastatic non-small cell lung cancer showed high concordance...
From the Journals
In NSCLC, delayed chemo yields survival benefit comparable to early chemo
In patients with non–small-cell lung cancer for whom adjuvant chemotherapy must be delayed for as long as 18 weeks, mortality outcomes are no...
From the Journals
Confirmation CT prevents unnecessary pulmonary nodule bronchoscopy
It’s probably a good idea to do a repeat CT the morning of a scheduled bronchoscopy to make sure the pulmonary nodule is still there, according to...
Case Reports
Paraneoplastic Isaacs syndrome leading to diagnosis of small-cell lung cancer
Original Report
Quality of life after surgery for pleural malignant mesothelioma – methodological considerations
Conference Coverage
VIDEO: Improved QOL an added benefit of pembrolizumab for NSCLC patients
First-line treatment of selected non–small-cell lung cancer patients with pembrolizumab produced significantly better quality of life, compared...
Conference Coverage
Toxicity high for SBRT in centrally-located lung tumors
VIENNA – Stereotactic body radiotherapy (SBRT) proved too toxic for many of patients recruited into a multinational phase II trial with centrally-...
Conference Coverage
c-Myc could be key to alisertib potential in small-cell lung cancer
VIENNA – The investigational agent alisertib plus paclitaxel improved progression-free survival, compared with paclitaxel plus placebo, in...
Conference Coverage
Durvalumab could offer option for difficult-to-treat NSCLC
VIENNA – In a heavily pretreated population of patients with non–small-cell lung cancer, the investigational checkpoint inhibitor durvalumab was...
From the Journals
KRAS-targeted T-cell therapy derails metastatic cancer
Adoptive transfer of cytotoxic T cells targeting a specific KRAS mutation (KRAS G12D) expressed by a metastatic colorectal cancer induced the...
Conference Coverage
Pembrolizumab proves promising for treating advanced SCLC
VIENNA – One-third of patients with extensive-stage small-cell lung cancer (SCLC) treated with the checkpoint inhibitor pembrolizumab achieved an...